Gisela Sitbon, Rolf Ehrnström and Simon Turner new board members of Gradientech
Uppsala, May 25, 2020. Gradientech is pleased to announce the appointment of three new members to the company's board including a new board chair, effective from May 14, 2020. The new board members have been recruited to strengthen the company with internationally acquired key competences to prepare for the market launch of Gradientech's in vitro diagnostic system for ultrarapid antibiotic susceptibility testing.
Dr. Gisela Sitbon, new chair of the board, has a research background within molecular biology, combined with more than 25 years of senior level experience from the life science industry. This includes business development and operational positions, as well as co-founding and managing a service-providing diagnostic company, later acquired by Capio. Sitbon has held numerous board positions within pharmaceutical, diagnostics and venture capital fund companies. She currently holds several chair positions and board appointments in private and stock market listed companies.
Rolf Ehrnström has extensive experience leading R&D at biotech and diagnostic companies like Amersham Pharmacia Biotech, Dako (acquired by Agilent) and the microfluidics pioneer company Gyros. Ehrnström is today CSO of the stock market listed diagnostics company lmmunovia, and appointed independent partner at Ventac Partners.
Simon Turner has a background as an investment analyst, with focus on diagnostics, medtech and digital solutions. Turner has solid experience from international due diligence work at French Kurma Partners, and later as Senior Manager Innovation Scout at Baxter lnternational.
"We are very happy to welcome our three new, highly experienced and competent board members. I am truly looking forward to working together to put Gradientech on the international map of leading diagnostic companies that provide solutions to global health issues," says CEO and Gradientech co-founder Sara Thorslund.
Gradientech has, in addition, recruited Hanna Gradin as new QA/Regulatory Affairs Manager, with solid experience from medical device and pharmaceutical companies like Galderma and Orexo. Gradin was mast recently working as auditor for the accredited certification body Nordic Certification.
For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se
